Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

PHASE2UnknownINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

April 30, 2018

Conditions
Non-alcoholic Steatohepatitis
Interventions
DRUG

MGL-3196

DRUG

Placebo

Trial Locations (26)

39202

Madrigal Research Site, Jackson

78233

Madrigal Research Site, Live Oak

90057

Madrigal Research Site, Los Angeles

Unknown

Madrigal Research Site, Dothan

Madrigal Research Site, Tucson

Madrigal Research Site, Coronado

Madrigal Research Site, Rialto

Madrigal Research Site, San Diego

Madrigal Research Site, Ventura

Madrigal Research Site, Englewood

Madrigal Research Site, Boca Raton

Madrigal Research Site, Lakewood Rch

Madrigal Research Site, Lauderdale Lakes

Madrigal Research Site, Miami

Madrigal Research Site, New Port Richey

Madrigal Research Site, Kansas City

Madrigal Research Site, Monroe

Madrigal Research Site, Baltimore

Madrigal Research Site, St Louis

Madrigal Research Site, Albuquerque

Madrigal Research Site, New York

Madrigal Research Site, Durham

Madrigal Research Site, Rapid City

Madrigal Research Site, San Antonio

Madrigal Research Site, Charlottesville

Madrigal Research Site, Seattle

Sponsors
All Listed Sponsors
lead

Madrigal Pharmaceuticals, Inc.

INDUSTRY

NCT02912260 - Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) | Biotech Hunter | Biotech Hunter